🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The KEYLYNK-006 trial determined that pembrolizumab plus maintenance olaparib did not improve PFS or OS vs pembrolizumab plus pemetrexed in previously untreated metastatic nonsquamous #NSCLC. Read more about the trial here: bit.ly/4gjGnxH #LCSM

This study aimed to investigate the prevalence of widespread guideline-discordant LDCT screening in a low-risk population. Read about its impact on LC epidemiology & healthcare utilization in this article by Kim SY et al: bit.ly/400GoRy #LCSM

The IASLC #Reviewer Workshop is a one-day workshop at #WCLC25, led by journal editors to train early and mid-career IASLC members in manuscript review. Applications open on January 24 to members in Europe. More information at: bit.ly/ReviewerWS #LCSM JTO & JTO CRR

Results from the MARS2 trial reported that pts who received extended pleurectomy decortication and chemotherapy had worse survival rates than those who received chemotherapy alone. The MARS2 results are controversial and the debate continues in JTO. bit.ly/49Yyf3z #LCSM

Women Against Lung Cancer in Europe promoted EPROPA to reduce the gap between relevant heterogeneity of molecular testing & cancer care. This program aimed to improve patient access to clinical trials by providing free-of-charge molecular profiling. bit.ly/4fUiTyu #LCSM

After evaluating the use of ISJETs & toxicity reporting practices in early phase clinical trials of #lungcancer treatments at #ASCO24, the authors determined that initiatives to increase objective language & specificity in toxicity reporting are warranted. bit.ly/4h0kLXO

This study proposes a diagnostic shift from static biomarker quantification in pts w/#NSCLC to assessing active immune pathways in order to provide more precise ICI treatment. Ultimately, the results implicate a need for combination diagnostics & therapies.bit.ly/4gnC1VT

Explore Argentina's past & present experience w/detecting & treating thoracic cancers in its current population. To learn more about demographics, tobacco control, & treatment despite the different healthcare options, click here: bit.ly/4humWTr #LCSM

PARP inhibitors may trigger innate immunity, upregulate PD-L1 expression & promote immune-mediated responses but maintenance w/olaparib+pembrolizumab didn't improve OS vs pembrolizumab + placebo in pts w/metastatic squamous #NSCLC, despite benefits in PFS. bit.ly/4iHtsXZ

The KEYLYNK-006 trial determined that pembrolizumab plus maintenance olaparib did not improve PFS or OS vs pembrolizumab plus pemetrexed in previously untreated metastatic nonsquamous #NSCLC. Read more about the trial here: bit.ly/4gjGnxH #LCSM

In patients with KRAS G12C-mutated non-Sq #NSCLC, sotorasib plus carboplatin/pemetrexed was found to demonstrate favorable efficacy especially in PD-L1 <1%, with manageable toxicity after an increased follow-up period. Learn More: bit.ly/41k4Mym #LCSM Hiroaki Akamatsu

Calles et al. evaluated lurbinectedin + pembrolizumab in relapsed #SCLC pts without prior immunotherapy. The combination showed promising efficacy, especially in platinum-sensitive pts. Read more: bit.ly/3Qp3xYl #LCSM Dr. Antonio Calles 🫁🚭

TY-9591, a deuterated osimertinib derivative, demonstrated a favorable safety profile & substantial efficacy in treating EGFR-mutated #NSCLC, especially in patients w/L858R mutations in this Phase 1 dose-escalation & dose-expansion study. Learn More: bit.ly/4i4Ml62 #LCSM

Treatment options for pts w/EGFR-mutated #NSCLC w/disease progression on or after osimertinib & platinum-based chemotherapy are limited, but amivantamab plus lazertinib may be a safe option despite present but manageable adverse affects. Learn More: bit.ly/439zNpM LCSM

Spira et al concluded that, despite #amivantamab's usual 67% IRR rate, prophylaxis with 8-mg oral dexamethasone meaningfully reduced IRRs. Read more about Spira et al's findings here: bit.ly/4gQ4nbs #LCSM @alexspiramdphd @vcspecialists

To combat resistance mechanisms involving adaptive reactivation of ERK in pts w/KRAS G12C #lungcancer, Kazi et al. show that the dual farnesyltransferase and geranylgeranyltransferase-1 inhibitor FGTI-2734 may improve the treatment outcomes of KRAS G12C. bit.ly/4hyMIVV

This manuscript from the IASLC Pathology Committee proposes a combined histologic and molecular algorithm in categorizing multiple lung adenocarcinomas into SPLCs or IPMs, specifically that genomic profiling by NGS should be performed whenever possible. bit.ly/4i4PvHJ

Here, Tuminello et al. predict that identifying malignant nodules in imaging ordered for other clinical reasons can help decrease the burden of NSCLC, especially in pts who do not qualify for LDCT screening. bit.ly/41qnPHD

Big news from JTO & JTO CRR! 📘 JTO Impact Factor: 20.8 🔹 #3 in Respiratory Medicine 🔹 #13 in Oncology A high-impact leader in thoracic oncology! 👏 for JTO CRR with an IF of 3.5, rising in both oncology & respiratory rankings! ➡️ bit.ly/3ZGbIol

Security Incident on IASLC's X Account We want to inform our community that our official X account, IASLC, was compromised earlier today. Please disregard any posts, messages, or links shared from our account during this period. ❓❓, contact us at [email protected]